Nova Mentis Pharma

Reaching new heights for more patients.

Nova Mentis Pharma is a company dedicated to the search for “New Beginnings” and providing high quality solutions towards unmet medical needs. Our focused strategy is to develop medicines that limit toxicities, off target side effects and improve our patients’ quality of life. Nova Mentis is pursuing these goals in a manner that is driven exclusively by needs of our patients and not high profits.

Our current pipeline includes NM-137 for the acute rescue of obstructive hypertrophic cardiomyopathy (HOCM) and atrial fibrillations (AF), NM-411 for pulmonary hypertension (PHT) and NM-911 for infectious diseases including Covid-19.  We are currently generating data that not only provide proof of concept but also significantly reduced off target effects while minimizing other general toxicities. True to our mission, we have a rigorous selection process for both medicines and disease indications enabling us to provide the best value for our patients.

We are presently examining partnerships as well as non-diluting collaborations with forward-looking biotechnology and pharmaceutical companies in the areas of Drug Development, Novel Device Engineering, and Product Advancement. Our partners are expected to hold the same high standards regarding our patients and our mission towards the treatment of current unmet medical needs.

We are also currently seeking support from visionary scientific foundations and private individuals as well as exploring the engagement of Venture Capital Firms.